Our CEO, Nathalie, has presented company strategy in front of many investors at Start West event in Rennes. She explained especially why our next fund rising is mandatory to develop internationally our exclusive BIOMIMESYS® products. She also shared with attendees her vision of the necessity of 3D cell culture to progress in drug discovery for complex diseases like neurodegererative, cardiometabolic ones and cancers.
So we are proud to be awarded by the special price of juries “prix coup de coeur des jurys” which highlight the robustness of our work and of our development strategy !
Thanks to its unique BIOMIMESYS® technology, which faithfully reproduces the matrix-extracellular of any type of organ while keeping these biological properties, HCS Pharma is able to reproduce a healthy or pathological mini-organ in vitro. As a result, HCS Pharma enables pharmaceutical companies to increase the relevance of their research efforts when choosing the drug candidate by shortening development times by 50% and drastically reducing the risk of failures during clinical studies on humans. This disruptive technology promises great progress in human health.
This prize will help us to make more useful contact with european ventures for our next fund rising. This year we will rise between 2 and 3 millions euros to secure the development of
BIOMIMESYS® technology for new organs and increase our international market (especialy USA and Asia).